LTP Stock Overview
A biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LTR Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.24 |
| 52 Week High | AU$2.16 |
| 52 Week Low | AU$0.24 |
| Beta | 0 |
| 11 Month Change | -20.06% |
| 3 Month Change | -29.83% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 298.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| LTP | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -8.2% | -16.3% | 0.9% |
| 1Y | n/a | 35.0% | 17.7% |
Return vs Industry: Insufficient data to determine how LTP performed against the Australian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LTP performed against the Australian Market.
Price Volatility
| LTP volatility | |
|---|---|
| LTP Average Weekly Movement | 13.5% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: LTP's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: LTP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | n/a | www.ltrpharma.com |
LTR Pharma Limited, a biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.
LTR Pharma Limited Fundamentals Summary
| LTP fundamental statistics | |
|---|---|
| Market cap | AU$188.41m |
| Earnings (TTM) | -AU$6.95m |
| Revenue (TTM) | AU$49.00k |
3,845x
P/S Ratio-27.1x
P/E RatioIs LTP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LTP income statement (TTM) | |
|---|---|
| Revenue | AU$49.00k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$49.00k |
| Other Expenses | AU$7.00m |
| Earnings | -AU$6.95m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.045 |
| Gross Margin | 100.00% |
| Net Profit Margin | -14,192.25% |
| Debt/Equity Ratio | 0% |
How did LTP perform over the long term?
See historical performance and comparison